Please assess the completion status of the following clinical trial:

Trial Title: Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of diverticular disease diagnosed for the first time or established by previous colonoscopy~* symptomatic episode of uncomplicated diverticular disease no more than 4 weeks prior to study entry~* patients who have given their free and informed consent.~Exclusion Criteria:~* acute diverticulitis (both complicated and uncomplicated)~* diverticular colitis~* active or recent peptic ulcer~* chronic renal insufficiency~* allergy to salicylates~* patients with intended or ascertained pregnancy, lactation~* women of childbearing age not using contraceptives~* lactulose-lactitol use in the two weeks before the enrolment and during the study~* presence of diverticulitis complications (fistulas, abscesses, and/or stenoses)~* use of probiotic preparations either prescribed or over-the counter within two weeks prior to study entry~* inability to give a valid informed consent or to properly follow the protocol~* patients with active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment were also acceptable)~* recent history or suspicion of alcohol abuse or drug addiction~* any severe pathology that can interfere with the treatment or the clinical or instrumental tests of the trial~* use of NSAIDS for one week before and throughout the study period (only paracetamol was permitted).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesalazine (Type: ACTIVE_COMPARATOR): Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
- Lactobacillus casei (Type: ACTIVE_COMPARATOR): Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
- Mesalazine plus Lactobacillus casei (Type: ACTIVE_COMPARATOR): Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
- Placebo (Type: PLACEBO_COMPARATOR): Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.

Based on this trial design, predict the completion outcome and termination type (if applicable).